EPISODE · Nov 20, 2025 · 1H 22M
Ep.7: Biotech M&A Insights: CVRs, Patent Cliffs & The Pfizer-Novo Bidding War
from Drug Dealin · host Drug Dealin Pod
SUMMARYIn this deep dive into biopharma M&A trends, Shivu and Kenny analyze 10 years of acquisition data from major pharma players, revealing rising deal volumes and the increasing prevalence of Contingent Value Rights (CVRs) as risk mitigation tools. The hosts dissect the unprecedented Pfizer-Novo bidding war over Metsera, examining how this “interloper” situation reflects broader industry dynamics around patent cliffs and portfolio diversification strategies. The episode provides insider perspectives on why investors never seem satisfied with “enough” M&A activity and how companies balance internal R&D with external acquisitions in their portfolio approach.CHAPTERS00:00 Introduction to M&A in Biopharma03:35 Understanding Contingent Value Rights (CVRs)06:47 Recent M&A Deals and Trends13:17 Impact of Patent Cliffs on M&A Activity17:43 The Portfolio Approach to Drug Development22:00 Current Trends in Deal Volume and CVR Usage28:58 Valuation Trends in Late-Stage Companies32:51 The Buyer-Seller Dynamic in Pharma Deals38:27 Evaluating CVRs and Acquirer Capabilities42:31 GenMab’s Strategic Acquisition and Market Positioning48:11 The Rise of the Biotech Middle Class55:49 The Aggressive Landscape of Pharma Hiring56:56 Innovation in RNA Interventions57:53 The Metsera Bidding War Begins01:00:11 Pfizer’s Acquisition Strategy Unfolds01:03:48 Regulatory Implications and Government Influence01:07:41 The Future of Metabolic Disease Treatments01:10:27 Interloper Behavior in Pharma Acquisitions01:15:35 The Role of Government Relationships in Pharma01:19:05 Concluding Thoughts on M&A Trends01:22:14 OUTRODOWNLOADS:M&A and CVR analysis available hereCONTACT US: Questions? Emal us at: [email protected] Follow Shivu on XSign up for Shivu's newsletter: Big Pharma Sharma Follow KennyDISCLAIMER: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.
What this episode covers
SUMMARYIn this deep dive into biopharma M&A trends, Shivu and Kenny analyze 10 years of acquisition data from major pharma players, revealing rising deal volumes and the increasing prevalence of Contingent Value Rights (CVRs) as risk mitigation tools. The hosts dissect the unprecedented Pfizer-Novo bidding war over Metsera, examining how this “interloper” situation reflects broader industry dynamics around patent cliffs and portfolio diversification strategies. The episode provides insider perspectives on why investors never seem satisfied with “enough” M&A activity and how companies balance internal R&D with external acquisitions in their portfolio approach.CHAPTERS00:00 Introduction to M&A in Biopharma03:35 Understanding Contingent Value Rights (CVRs)06:47 Recent M&A Deals and Trends13:17 Impact of Patent Cliffs on M&A Activity17:43 The Portfolio Approach to Drug Development22:00 Current Trends in Deal Volume and CVR Usage28:58 Valuation Trends in Late-Stage Companies32:51 The Buyer-Seller Dynamic in Pharma Deals38:27 Evaluating CVRs and Acquirer Capabilities42:31 GenMab’s Strategic Acquisition and Market Positioning48:11 The Rise of the Biotech Middle Class55:49 The Aggressive Landscape of Pharma Hiring56:56 Innovation in RNA Interventions57:53 The Metsera Bidding War Begins01:00:11 Pfizer’s Acquisition Strategy Unfolds01:03:48 Regulatory Implications and Government Influence01:07:41 The Future of Metabolic Disease Treatments01:10:27 Interloper Behavior in Pharma Acquisitions01:15:35 The Role of Government Relationships in Pharma01:19:05 Concluding Thoughts on M&A Trends01:22:14 OUTRODOWNLOADS:M&A and CVR analysis available hereCONTACT US: Questions? Emal us at: [email protected] Follow Shivu on XSign up for Shivu's newsletter: Big Pharma Sharma Follow KennyDISCLAIMER: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.
NOW PLAYING
Ep.7: Biotech M&A Insights: CVRs, Patent Cliffs & The Pfizer-Novo Bidding War
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.